Free Shipping Over A$199 — Research Only
Retatrutide 10mg - Research peptide Australia
In Stock

Retatrutide 10mg

A$300.00 – A$1200.00

As low as A$240.00/unit

Free shipping over A$199 HPLC Verified Discreet Packaging
1

Research Use Only: This product is sold for laboratory and in-vitro research purposes. Not for human consumption or therapeutic use.

Product Details

Retatrutide (LY-3437943) is a novel triple-agonist peptide that targets GIP, GLP-1, and glucagon receptors simultaneously. This 10mg lyophilized preparation is designed for advanced metabolic research. Clinical trial data has demonstrated significant interest in its effects on body weight regulation, glycemic control, and energy expenditure through its unique tri-agonist mechanism. Retatrutide represents a new frontier in incretin-based research, with studies examining its pharmacokinetics and metabolic effects. 99%+ purity, HPLC-MS tested. For laboratory and research use only.

Health Benefits of Retatrutide 10mg

Triple Receptor Agonist

Retatrutide is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. This tri-agonist approach is unique among incretin-based peptides and has shown unprecedented efficacy in clinical trials for metabolic research.

Significant Weight Loss Research

Phase 2 clinical trials published in the New England Journal of Medicine demonstrated up to 24.2% body weight reduction over 48 weeks — the highest weight loss ever achieved with a single pharmacological agent in clinical trials.

Improved Glycaemic Control

Research shows retatrutide significantly improves HbA1c, fasting glucose, and insulin sensitivity. The combination of GLP-1 and GIP receptor activation provides dual incretin benefit for glucose metabolism research.

Glucagon-Mediated Energy Expenditure

Unlike dual GLP-1/GIP agonists (e.g. tirzepatide), retatrutide's glucagon receptor activation increases energy expenditure, hepatic lipid oxidation, and thermogenesis. This third mechanism contributes to its superior weight loss efficacy in research models.

Liver Fat Reduction

Clinical data suggests retatrutide significantly reduces hepatic fat content, with studies showing potential applications in non-alcoholic fatty liver disease (NAFLD/MASH) research. Glucagon receptor activation directly promotes hepatic fat oxidation.

Cardiovascular Metabolic Benefits

Research demonstrates improvements in cardiovascular risk markers including blood pressure, triglycerides, and inflammatory markers, suggesting broad cardiometabolic benefits beyond weight management.

Note: The health benefits listed above are based on published scientific research and clinical studies. Individual results may vary. This product is sold for research purposes only — not for human consumption. Always consult published literature for detailed study methodologies and findings.

Frequently Asked Questions — Retatrutide 10mg

What is Retatrutide?

Retatrutide (LY3437943) is a novel triple-acting peptide agonist developed by Eli Lilly. It simultaneously activates GLP-1, GIP, and glucagon receptors — making it the first tri-agonist in its class. Phase 2 clinical trials have shown unprecedented efficacy in weight management and metabolic research.

How does Retatrutide compare to Semaglutide and Tirzepatide?

Semaglutide is a GLP-1 receptor agonist (single target). Tirzepatide is a dual GLP-1/GIP agonist (two targets). Retatrutide adds glucagon receptor activation as a third target, increasing energy expenditure and hepatic fat oxidation. Phase 2 trials showed retatrutide achieved greater weight loss (24.2%) than either semaglutide (~15%) or tirzepatide (~22.5%).

What makes the glucagon receptor important?

Glucagon receptor activation increases hepatic glucose output, promotes fat oxidation in the liver, increases energy expenditure, and enhances thermogenesis. These effects complement the appetite-suppressing and insulin-sensitising actions of GLP-1 and GIP, creating a comprehensive metabolic effect.

Can I buy Retatrutide in Australia?

Yes — OzTideLab ships Retatrutide 10mg across Australia via Australia Post. Free standard shipping on orders over A$199. HPLC-verified ≥98% purity, discreet packaging, and PayID/Osko payment accepted.

Research Applications

This peptide is supplied for in-vitro laboratory research only. Common research applications include receptor binding assays, cell culture studies, structure-activity relationship analysis, and bioassay development. Researchers should consult relevant literature for specific experimental protocols.

Storage & Handling

  • Store lyophilised powder at -20°C for long-term stability
  • Short-term storage: 2-8°C (refrigerated)
  • Protect from light, moisture, and repeated freeze-thaw cycles
  • Once reconstituted, use within the recommended timeframe

Purity & HPLC Analysis

Every batch is independently verified via High-Performance Liquid Chromatography (HPLC) to confirm ≥98% purity. Mass spectrometry (MS) is used for molecular identity confirmation. Certificates of Analysis (CoA) are available on request — email support@oztidelab.com with your order number.

Reconstitution Guidelines

  • Use bacteriostatic water or sterile water for reconstitution
  • Add solvent slowly along the vial wall — do not shake
  • Gently swirl until fully dissolved (clear solution)
  • Store reconstituted solution at 2-8°C and use within 28 days
  • Use sterile technique throughout to prevent contamination

HPLC Verified

≥98% purity certified

Australian Owned

Local team, local support

Discreet Shipping

Plain packaging AU-wide

Research Grade

Lab-quality peptides